Page last updated: 2024-12-06
a 75925
Description
Research Excerpts
Clinical Trials
Roles
Classes
Pathways
Study Profile
Bioassays
Related Drugs
Related Conditions
Protein Interactions
Research Growth
Market Indicators
Description
A 75925: has HIV antiviral & HIV type 1 protease inhibitory activity [Medical Subject Headings (MeSH), National Library of Medicine, extracted Dec-2023]
Cross-References
| ID Source | ID |
|---|---|
| PubMed CID | 72290 |
| CHEMBL ID | 289846 |
| SCHEMBL ID | 6446780 |
| MeSH ID | M0199091 |
Synonyms (22)
| Synonym |
|---|
| 142861-15-2 |
| 2,5-diamino-n,n'-bis(n-benzyloxycarbonylvalyl)-1,6-diphenyl-3(r),4(r)-hexanediol |
| l-iditol, 1,2,5,6-tetradeoxy-2,5-bis[[(2s)-3-methyl-1-oxo-2-[[(phenylmethoxy)carbonyl]amino]butyl]amino]-1,6-diphenyl- |
| bzocvalphe[dichoh(rr)]phevalbzoc |
| 129467-48-7 |
| benzyl n-[(1s)-1-[[(1s,2r,3r,4s)-1-benzyl-4-[[(2s)-2-(benzyloxycarbonylamino)-3-methyl-butanoyl]amino]-2,3-dihydroxy-5-phenyl-pentyl]carbamoyl]-2-methyl-propyl]carbamate |
| a 75925 |
| q8024 |
| a-75925 |
| CHEMBL289846 , |
| benzyl n-[(2s)-1-[[(2s,3r,4r,5s)-3,4-dihydroxy-5-[[(2s)-3-methyl-2-(phenylmethoxycarbonylamino)butanoyl]amino]-1,6-diphenylhexan-2-yl]amino]-3-methyl-1-oxobutan-2-yl]carbamate |
| bdbm50064200 |
| benzyl (2s,2''s)-1,1''-((2s,3r,4r,5s)-3,4-dihydroxy-1,6-diphenylhexane-2,5-diyl)bis(azanediyl)bis(3-methyl-1-oxobutane-2,1-diyl)dicarbamate |
| {(s)-1-[(1s,2r,3r,4s)-1-benzyl-4-((s)-2-benzyloxycarbonylamino-3-methyl-butyrylamino)-2,3-dihydroxy-5-phenyl-pentylcarbamoyl]-2-methyl-propyl}-carbamic acid benzyl ester |
| bzocvalphe(dichoh(rr))phevalbzoc |
| l-iditol, 1,2,5,6-tetradeoxy-2,5-bis(((2s)-3-methyl-1-oxo-2-(((phenylmethoxy)carbonyl)amino)butyl)amino)-1,6-diphenyl- |
| (2(s),5(s))-1,2,5,6-tetradeoxy-2,5-bis((3-methyl-1-oxo-2-(((phenylmethoxy)carbonyl)amino)butyl)amino)-1,6-diphenyl-l-iditol |
| l-iditol, 1,2,5,6-tetradeoxy-2,5-bis((3-methyl-1-oxo-2-(((phenylmethoxy)carbonyl)amino)butyl)amino)-1,6-diphenyl-, (2(s),5(s))- |
| SCHEMBL6446780 |
| dibenzyl ((2s,2's)-(((2s,3r,4r,5s)-3,4-dihydroxy-1,6-diphenylhexane-2,5-diyl)bis(azanediyl))bis(3-methyl-1-oxobutane-1,2-diyl))dicarbamate |
| bdbm586099 |
| AKOS040747671 |
Research Excerpts
Pharmacokinetics
| Excerpt | Reference | Relevance |
|---|---|---|
| " Additional pharmacokinetic studies in dogs and monkeys revealed the potential utility of A-77003 as an intravenous anti-HIV agent." | ( Antiviral and pharmacokinetic properties of C2 symmetric inhibitors of the human immunodeficiency virus type 1 protease. Bryant, P; Codacovi, L; Kempf, DJ; Knigge, MF; Kohlbrenner, WE; Marsh, KC; Norbeck, DW; Paul, DA; Vasavanonda, S; Wang, XC, 1991) | 0.28 |
Bioavailability
| Excerpt | Reference | Relevance |
|---|---|---|
| " After administration of the inhibitors to rats, short half-lives and, with two notable exceptions, moderate oral bioavailability were observed." | ( Antiviral and pharmacokinetic properties of C2 symmetric inhibitors of the human immunodeficiency virus type 1 protease. Bryant, P; Codacovi, L; Kempf, DJ; Knigge, MF; Kohlbrenner, WE; Marsh, KC; Norbeck, DW; Paul, DA; Vasavanonda, S; Wang, XC, 1991) | 0.28 |
[information is derived through text-mining from research data collected from National Library of Medicine (NLM), extracted Dec-2023]
Protein Targets (2)
Inhibition Measurements
| Protein | Taxonomy | Measurement | Average | Min (ref.) | Avg (ref.) | Max (ref.) | Bioassay(s) |
|---|---|---|---|---|---|---|---|
| Protease | Human immunodeficiency virus 1 | IC50 (µMol) | 0.0002 | 0.0001 | 0.2248 | 7.3200 | AID161507; AID162040 |
| Protease | Human immunodeficiency virus 1 | IC50 (µMol) | 0.0020 | 0.0000 | 0.8176 | 9.8500 | AID449367 |
| [prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023] | |||||||
Bioassays (5)
| Assay ID | Title | Year | Journal | Article |
|---|---|---|---|---|
| AID449367 | Inhibition of HIV1 protease expressed in Escherichia coli K12 assessed as inhibition of enzyme activity | 2009 | European journal of medicinal chemistry, Nov, Volume: 44, Issue:11 | 3D-QSAR CoMFA/CoMSIA models based on theoretical active conformers of HOE/BAY-793 analogs derived from HIV-1 protease inhibitor complexes. |
| AID161507 | Inhibitory activity was measured against wild-type HIV-1 protease | 1998 | Journal of medicinal chemistry, May-07, Volume: 41, Issue:10 | Cyclopropane-derived peptidomimetics. Design, synthesis, evaluation, and structure of novel HIV-1 protease inhibitors. |
| AID1318772 | Inhibition of recombinant HIV-1 protease using Lys-Ala-Arg-Val-Tyr-Phe(NO2)-Glu-AlaNle-NH2 as substrate | 2016 | Journal of medicinal chemistry, 10-13, Volume: 59, Issue:19 | The "Cyclopropyl Fragment" is a Versatile Player that Frequently Appears in Preclinical/Clinical Drug Molecules. |
| AID162040 | Inhibition of HIV-1 protease | 1994 | Journal of medicinal chemistry, Apr-15, Volume: 37, Issue:8 | Application of the three-dimensional structures of protein target molecules in structure-based drug design. |
| AID1799479 | Inhibition Assay from Article 10.1016/S1074-5521(02)00184-9: \\A quick diversity-oriented amide-forming reaction to optimize P-subsite residues of HIV protease inhibitors.\\ | 2002 | Chemistry & biology, Aug, Volume: 9, Issue:8 | A quick diversity-oriented amide-forming reaction to optimize P-subsite residues of HIV protease inhibitors. |
| [information is prepared from bioassay data collected from National Library of Medicine (NLM), extracted Dec-2023] | ||||
Research
Studies (7)
| Timeframe | Studies, This Drug (%) | All Drugs % |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 4 (57.14) | 18.2507 |
| 2000's | 2 (28.57) | 29.6817 |
| 2010's | 1 (14.29) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| [information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023] | ||
Market Indicators
Research Demand Index: 12.19
According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be weak demand-to-supply ratio for research on this compound.
| This Compound (12.19) All Compounds (24.57) |
Study Types
| Publication Type | This drug (%) | All Drugs (%) |
|---|---|---|
| Trials | 0 (0.00%) | 5.53% |
| Reviews | 1 (14.29%) | 6.00% |
| Case Studies | 0 (0.00%) | 4.05% |
| Observational | 0 (0.00%) | 0.25% |
| Other | 6 (85.71%) | 84.16% |
| [information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023] | ||